Document is current
Any future updates will be listed below
-
Authors
Rieckmann, Lisa-Marie
Spohn, Michael
Ruff, Lisa
Agorku, David
Becker, Lisa
Borchers, Alina
Krause, Jenny
O’Reilly, Roisin
Hille, Jurek
Velthaus-Rusik, Janna-Lisa
Beumer, Niklas
Günther, Armin
Willnow, Lena
Imbusch, Charles D.
Iglauer, Peter
Simon, Ronald
Franzenburg, Sören
Winter, Hauke
Thomas, Michael
Bokemeyer, Carsten
Gagliani, Nicola
Krebs, Christian F.
Sprick, Martin
Hardt, Olaf
Riethdorf, Sabine
Trumpp, Andreas
Stoecklein, Nikolas H.
Peine, Sven
Rosenstiel, Philipp
Pantel, Klaus
Loges, Sonja
Janning, Melanie
-
Funding
Funding for this research was provided by:
Hector Stiftung II
Landesforschungsförderung Hamburg (LFF GK10, LFF GK10, LFF GK10)
European Union Seventh Framework Program (FP7/2007-2013 - CancerID, FP7/2007-2013 - CancerID)
Bristol-Myers Squibb (CA209-8RG, CA209-8RG)
European Research Council (758713-ELIMINATE)
Margarete Clemens Stiftung
- License Information
-
More Information
Article History
Received: 27 January 2024
Accepted: 18 March 2024
First Online: 8 May 2024
Declarations
:
: All patients provided written informed consent and the study was approved by the Medical Ethical Committee Hamburg, Germany (PV5392).
: Not applicable.
: DA and OH are employees of Miltenyi Biotec B.V. & Co. KG. CB: honoraria and/or advisory board from AstraZeneca, Bayer, Berlin Chemie, BMS, Merck, Roche, Novartis, Sanofi, Lilly/ImClone and travel expenses from BMS, Merck, Pfizer and Sanofi. SL received funding from BerGenBio, Bristol Myers Squibb, Eli Lilly, Roche Pharma and ADC Therapeutics; consulting fees from BerGenBio, BMS, Boehringer Ingelheim, Eli Lilly, Roche Pharma, Medac, Sanofi Aventis, Novartis, AstraZeneca, Pfizer, Takeda, Amgen, Bayer, Janssen and Merck; money for presentations/speakers bureaus from BerGenBio, BMS, Boehringer Ingelheim, Eli Lilly, Roche Pharma, Medac, Sanofi Aventis, Novartis, AstraZeneca, Pfizer, Takeda, Amgen, Bayer, Jannssen and Merck; travel support from BerGenBio, BMS, Boehringer Ingelheim, Eli Lilly, Roche Pharma, Medac, Sanofi Aventis, Novartis, AstraZeneca, Pfizer, Takeda, Amgen, Bayer, Janssen and Merck. MJ: received research support (material) from Miltenyi and funding from Bristol Myers Squibb; speakers honoraria and /or advisory board from Roche, Amgen, AstraZeneca, Novartis, Takeda and travel support from AstraZeneca.
